コーパス検索結果 (１語後でソート)
通し番号をクリックするとPubMedの該当ページを表示します
1 alanine ((18)F-FDOPA) is another interesting radiopharmaceutical.
2 h, 2 h, and 4 h after administration of the radiopharmaceutical.
3 amycin as a phosphatidylethanolamine-binding radiopharmaceutical.
4 c focus is obtaining a timely injection of a radiopharmaceutical.
5 istribution, and radiation dosimetry of this radiopharmaceutical.
6 imetry of 2 members of this new class of PET radiopharmaceutical.
7 ly half that of patients injected with other radiopharmaceuticals.
8 ocedures in the daily preparation of (99m)Tc radiopharmaceuticals.
9 ure syringe-and-vial radiolabeling of (68)Ga radiopharmaceuticals.
10 find any particular concern about the use of radiopharmaceuticals.
11 Drug Administration (FDA) reviews diagnostic radiopharmaceuticals.
12 ncertainty of the internal doses of 7 common radiopharmaceuticals.
13 uncertainty was developed and applied for 7 radiopharmaceuticals.
14 of absorbed doses and effective doses for 7 radiopharmaceuticals.
15 less successful when applied to evaluate new radiopharmaceuticals.
16 etic strategy for synthesis of (18)F-labeled radiopharmaceuticals.
17 r images, and use of pseudoplanar images and radiopharmaceuticals.
18 s been used to label various new therapeutic radiopharmaceuticals.
19 f 99mTc is a promising route to supply 99mTc radiopharmaceuticals.
20 seen in nuclear reactors, is emitted by some radiopharmaceuticals.
21 irradiation dose delivered to BM by injected radiopharmaceuticals.
22 predict the response of cell populations to radiopharmaceuticals.
23 omparable to that of other commonly used PET radiopharmaceuticals.
24 y being used to synthesize positron-emitting radiopharmaceuticals.
25 for evaluation of using them as PET imaging radiopharmaceuticals.
26 latory and payment considerations of new PET radiopharmaceuticals.
27 ntially when labeled with (131)I therapeutic radiopharmaceuticals.
28 ker research and discovery and validation of radiopharmaceuticals.
29 sing patient normal-organ kinetics for the 2 radiopharmaceuticals.
30 t impact on the synthesis and development of radiopharmaceuticals.
31 ive doses (MTBEDs) arising from the combined radiopharmaceuticals.
32 ium are unique compared with previously used radiopharmaceuticals.
33 for the rapid, high-throughput screening of radiopharmaceuticals.
34 as F-Lu-rhPSMA, are unique features of these radiopharmaceuticals.
35 ient for analysis of radiochemical purity of radiopharmaceuticals.
36 TATATE and for kidney dosimetry in different radiopharmaceuticals.
37 biodosimeter with beta-emitting therapeutic radiopharmaceuticals.
38 ew concept in achieving targeted delivery of radiopharmaceuticals.
39 or use in the synthesis and discovery of PET radiopharmaceuticals.
40 HBED-NN)] for potential use in gallium-based radiopharmaceuticals.
41 t can be used for imaging and treatment with radiopharmaceuticals.
42 son Foundation, Weston Brain Institute, Avid Radiopharmaceuticals.
43 Most reports (96.8%) were for diagnostic radiopharmaceuticals.
47 odonium(III) ylide precursor, to prepare the radiopharmaceutical (18)F-3-fluoro-5-[(pyridin-3-yl)ethy
48 ole-body effective dose for the experimental radiopharmaceutical (18)F-FdCyd administered in conjunct
50 vitro and in vivo uptake of pyrimidine-based radiopharmaceuticals ((18)F-FEAU) comparable to that of
51 the safety and effectiveness of a novel PET radiopharmaceutical, (18)F-3-fluoro-5-[(pyridin-3-yl)eth
54 only (131)I-tositumomab, and 24.9% used both radiopharmaceuticals; 37.9% did not treat NHL with radio
57 f PRRT with regard to the most commonly used radiopharmaceuticals, (90)Y-DOTATOC and (177)Lu-DOTATATE
58 the pharmacokinetics of the tricarbonyl core radiopharmaceutical (99m)Tc(CO)(3)-nitrilotriacetic acid
59 The pharmacokinetics of the tricarbonyl core radiopharmaceutical (99m)Tc(CO)3-nitrilotriacetic acid (
60 luate the MTD, we adjusted the dosage of the radiopharmaceutical according to body surface area (BSA)
65 ear Medicine Society (BNMS) online database (Radiopharmaceutical Adverse Events and Product Defects)
66 the study period, there were 204 reports of radiopharmaceutical adverse reactions, of which 13 were
68 r Medicine should choose the membership of a radiopharmaceutical advisory committee, and the FDA shou
72 in designing treatment plans for therapeutic radiopharmaceuticals, an applet software application cal
73 or because a causal relationship between the radiopharmaceutical and the adverse reaction could not b
74 topes to enable roles for (90)Y complexes as radiopharmaceuticals and (86)Y tracers for positron emis
75 signed to automate the extraction of data on radiopharmaceuticals and administered activities from nu
77 This article reviews radiation dosimetry for radiopharmaceuticals and also CT given the recent prolif
78 potential in clinics likely will require new radiopharmaceuticals and applications other than whole-b
81 that, this review focuses on promising novel radiopharmaceuticals and describes their preclinical and
82 al perspective in the realm of bone-targeted radiopharmaceuticals and discuss how these agents compar
83 ng decisions on Medicare coverage of new PET radiopharmaceuticals and imaging procedures that are cur
85 uptake curves can be used to rapidly screen radiopharmaceuticals and other cytotoxic agents to formu
87 The understanding of the biodistribution of radiopharmaceuticals and the lesion uptake of the (18)F(
88 s (AEs) to PET radiopharmaceuticals, non-PET radiopharmaceuticals, and adjunctive nonradioactive phar
90 ection (p.i.) scan time points for different radiopharmaceuticals applied to neuroendocrine tumors an
92 d radiosynthesis protocols for (18)F-labeled radiopharmaceuticals are an indispensable but often over
93 s have been established, and therefore these radiopharmaceuticals are being investigated for clinical
96 ATOC and (68)Ga-PSMA-HBED-CC investigational radiopharmaceuticals are currently being studied clinica
97 l trials of palliative radiation therapy and radiopharmaceuticals are emphasized, and new concepts in
98 astrin-releasing peptide receptors targeting radiopharmaceuticals are small molecules with fast blood
101 significant doses of scVEGF/(177)Lu, a novel radiopharmaceutical based on a recombinant single-chain
102 ethods and evaluated dose errors for several radiopharmaceuticals based on effective half-life distri
107 ally showed promise as an infection-specific radiopharmaceutical, but subsequent investigations were
108 yer chromatography (iTLC), HPLC and pH), the radiopharmaceutical can be directly administered to pati
109 nd its uptake in HER2-positive lesions, this radiopharmaceutical can offer new therapeutic options to
111 ate tracer selection, the impact of improved radiopharmaceutical chemistry in radiotracer development
112 core of this process, and radiometals offer radiopharmaceutical chemists a tremendous range of optio
114 niques, the development of a liposome loaded radiopharmaceutical construct for enhanced delivery via
115 lay a pivotal role in (18) F-fluorination of radiopharmaceuticals containing non-activated arenes.
116 and CT and combined PET and MRI using novel radiopharmaceuticals, create new opportunities for imagi
117 s have fueled efforts to develop novel SPECT radiopharmaceuticals, creating new chelators and prosthe
118 xy-3'-(18)F-fluorothymidine ((18)F-FLT) is a radiopharmaceutical depicting tumor cell proliferation w
121 excretion into the bladder similar to other radiopharmaceuticals developed for gamma-camera renograp
124 This computational method can be used in the radiopharmaceutical development process for ligand and t
126 advantages and limitations of the available radiopharmaceuticals, discusses quality control elements
133 ion, sedation, local and general anesthesia, radiopharmaceutical doses, radiation risk, and dose redu
135 Administration (FDA) approval of diagnostic radiopharmaceuticals (DRs) are described in laws that br
136 first challenged the common assumption that radiopharmaceutical effective half-lives across the popu
140 be a new positron emission tomographic (PET) radiopharmaceutical, fluorine 18 ((18)F) 2-fl uoropropio
144 udy was to validate (18)F-FDS as a potential radiopharmaceutical for imaging bacterial infection long
145 state-specific membrane antigen (PSMA)-based radiopharmaceutical for imaging prostate cancer (PCa).
146 suggests that (68)Ga-RM2 is a promising PET radiopharmaceutical for localization of disease in patie
147 ptide ((18)F-FtRGD) to determine the optimal radiopharmaceutical for measuring the early treatment re
148 Rubidium-ARMI ((82)Rb as an Alternative Radiopharmaceutical for Myocardial Imaging) is a multice
149 tion the conjugate as a potential diagnostic radiopharmaceutical for patients suffering from small-ce
150 fluoro-L-DOPA ([(18)F]FDOPA) is a diagnostic radiopharmaceutical for positron emission tomography (PE
151 istribution investigation of the use of this radiopharmaceutical for possible future use in the diagn
153 safety data for (68)Ga-NeoBOMB1, a promising radiopharmaceutical for targeting GRPR-expressing tumors
154 n vitro and in vivo evaluation of this novel radiopharmaceutical for the detection of IL2 receptor-po
155 dopa ((18)F-FDOPA) has proven to be a useful radiopharmaceutical for the evaluation of presynaptic do
156 the most frequently used radioisotope in PET radiopharmaceuticals for both clinical and preclinical r
157 inherent optical emissions from the decay of radiopharmaceuticals for Cerenkov luminescence imaging (
158 ding hybrid imaging, the introduction of new radiopharmaceuticals for diagnosis and therapy, and the
159 (PSMA) comprise a rapidly emerging class of radiopharmaceuticals for diagnostic imaging of prostate
160 profile of PF-367 is ideal for discovery of radiopharmaceuticals for GSK-3 in the central nervous sy
161 is a well-established target for developing radiopharmaceuticals for imaging and therapy of prostate
162 ive molecular targets for developing peptide radiopharmaceuticals for melanoma imaging and therapy.
163 is the most commonly used isotope to prepare radiopharmaceuticals for molecular imaging by positron e
165 stigation of (18)F-labeled rhodamines as PET radiopharmaceuticals for myocardial perfusion imaging.
167 n and high labeling yields of (68)Ga-labeled radiopharmaceuticals for routine medical application.
168 g ligands such as RPS-027 as next-generation radiopharmaceuticals for targeted alpha-therapy using (2
170 lly introduced as a new class of theranostic radiopharmaceuticals for the treatment of prostate cance
173 f (EH)3 on the biodistribution of 2 peptidic radiopharmaceuticals, Glu-urea-Lys(Ahx)-HBED-CC and TATE
174 e of (131)I-o-iodohippuran ((131)I-OIH), the radiopharmaceutical gold standard for the measurement of
176 Cholescintigraphy with (99m)Tc-hepatobiliary radiopharmaceuticals has been an important, clinically u
179 urally diverse and novel clinically relevant radiopharmaceuticals have been synthesized with both hig
180 modest economic prospects of most diagnostic radiopharmaceuticals have not attracted keen interest fr
182 utic efficacy, 2 groups of mice received the radiopharmaceutical in a median dose of either 165 MBq (
184 There were no observed adverse events to the radiopharmaceutical in the immediate or delayed time fra
186 ecular diagnostic markers, and validation of radiopharmaceuticals in both rodent and human cell lines
190 vestigation of the pharmacokinetics of these radiopharmaceuticals in vivo in humans is crucial for pe
191 azole ((11)C-PS13), a COX-1 PET neuroimaging radiopharmaceutical, in OvCa xenograft mouse models.
192 s expended on new pharmaceuticals, including radiopharmaceuticals, in order to identify the most prom
193 18) F-difluoromethylarene drug analogues and radiopharmaceuticals including Claritin, fluoxetine (Pro
194 xit after PET/CT imaging or just after SPECT radiopharmaceutical injection appears to be safe from a
196 tal critical component of a radiometal-based radiopharmaceutical is the chelator, the ligand system t
199 to conclude that the major advantage of such radiopharmaceuticals is the apparent lack of suitable (1
200 a (68)Ge/(68)Ga generator into a lyophilized radiopharmaceutical kit in 1 step without manipulation.
202 rable to other previously reported RGD-based radiopharmaceuticals labeled with (68)Ga and (18)F.
203 e the pharmacokinetic properties of peptidic radiopharmaceuticals, leading to reduced uptake in organ
204 ate that the investigational (64)Cu-DOTATATE radiopharmaceutical may provide diagnostic and logistica
205 ssing cells when compared with the reference radiopharmaceuticals, medium-to-low lipophilicity, and h
206 AC), of a diagnostic/therapeutic convergence radiopharmaceutical, namely (64)Cu-/(177)Lu-labeled anti
207 tudy was to investigate the combination of a radiopharmaceutical, nanoparticles and ultrasound (US) e
208 the incidence of adverse events (AEs) to PET radiopharmaceuticals, non-PET radiopharmaceuticals, and
210 gan doses from the administered activity and radiopharmaceutical of each examination were provided.
211 68)Ga-DOTATATE, and CT/MRI and should be the radiopharmaceuticals of choice in this rare group of pat
215 ensures the removal of (68)Ge before (68)Ga-radiopharmaceutical preparation and high labeling yields
216 al and clinical results of these new peptide radiopharmaceuticals present an optimistic outlook for c
217 f adapting these new reactions for automated radiopharmaceutical production has revealed limitations
218 asingly sophisticated methods for generating radiopharmaceuticals, provide the potential for either r
219 void rapid clearance as faced with molecular radiopharmaceuticals, provides unique opportunities to t
221 art 1 of this review addressed the available radiopharmaceuticals, quality control, and quantitative
222 ence of skeletal-related events, whereas the radiopharmaceutical radium-223 is shown to reduce the in
223 rrioxamine B (DFO), describes its effects on radiopharmaceutical reactivity toward antigen, and offer
226 ce while optimizing the ratio of 2 different radiopharmaceuticals required to maximize tumor control.
227 s, which makes them excellent candidates for radiopharmaceutical research; hence their synthesis and
232 this concept to true theranostic radiohybrid radiopharmaceuticals, such as F-Lu-rhPSMA, are unique fe
233 ation may change with the development of new radiopharmaceuticals, such as prostate-specific membrane
234 reido)-pentanedioic acid) is a promising PET radiopharmaceutical targeting prostate-specific membrane
236 essed in prostate cancer, and small-molecule radiopharmaceuticals targeting PSMA rapidly detect the l
238 near-infrared cyanine dye, to tilmanocept, a radiopharmaceutical that binds to a receptor specific to
239 phoramidate PSMA-targeting (18)F-labeled PET radiopharmaceutical that demonstrates similar biodistrib
243 ocedures for cancer therapy are administered radiopharmaceuticals that emit various types of radiatio
244 range of substrates, facilitating access to radiopharmaceuticals that were challenging to synthesize
245 assessed all reports of adverse reactions to radiopharmaceuticals that were submitted to the British
246 able (68)Ga-DOTATOC (or other (68)Ga-labeled radiopharmaceuticals) that are suitable for routine appl
248 ilarly, compelling science supporting select radiopharmaceutical therapies in oncology has been overs
249 performing routine personalized dosimetry in radiopharmaceutical therapies, interest in single-time-p
251 n and optimization of alpha-particle emitter radiopharmaceutical therapy (alphaRPT) is especially imp
253 st time to host a joint workshop on systemic radiopharmaceutical therapy (RPT) to specifically addres
256 a similar chelator/scaffold combination for radiopharmaceutical therapy based on the structure of 6.
257 te-specific membrane antigen (PSMA)-targeted radiopharmaceutical therapy is a new option for patients
265 acoustic-cavitation-sensitive liposomes with radiopharmaceuticals this research represents a new conc
266 efficiency can require larger amounts of the radiopharmaceutical to be administered, possibly leading
267 for cancer treatment but require any derived radiopharmaceutical to be essentially free of impurities
270 roved alpha-emitter, (223)RaCl2 is the first radiopharmaceutical to show an increase in overall survi
271 process and assist in bringing new targeted radiopharmaceuticals to approval over the next few years
272 was unrealistic to expect trials of new PET radiopharmaceuticals to directly demonstrate a health be
273 udy was to use estrogen- and progestin-based radiopharmaceuticals to image ERalpha and PR in mouse ma
275 is considered a nontoxic, safe-to-administer radiopharmaceutical unlikely to cause adverse effects in
279 2011, PET studies increased, and therapeutic radiopharmaceutical use and bone scintigraphy were uncha
282 1)I-metaiodobenzylguanidine ((131)I-MIBG), a radiopharmaceutical used for the therapy of neuroendocri
283 a-iodobenzylguanidine (mIBG) is an important radiopharmaceutical used in the diagnosis and treatment
288 Tumor and kidney uptake of the respective radiopharmaceuticals was measured 24 h after injection b
289 , a high-affinity VLA-4 peptidomimetic-based radiopharmaceutical, was evaluated in alpha4 knock-out m
290 silicon-fluoride-acceptor (SiFA)-conjugated radiopharmaceuticals, we developed inhibitors of the pro
292 st line of pursuit in the development of new radiopharmaceuticals-whether antibodies, peptides, or sm
293 erapy success, technical advances, and novel radiopharmaceuticals will all contribute to sustained gr
294 ons are already approved for human use, more radiopharmaceuticals will enter clinical practice in the
297 these radioisotopes allow the preparation of radiopharmaceuticals with identical pharmacokinetics use
298 2) of an SnO2-based generator, affording the radiopharmaceuticals with specific activities greater th